Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr. Landgren on the Rationale For Examining Whole Genome Sequencing in Smoldering Myeloma

April 26th 2021

Ola Landgren, MD, PhD, discusses the rationale behind examining whole-genome sequencing in smoldering myeloma.

Dr. Maura on the Significance of Studying Myeloma Genomic Defining Events

April 26th 2021

Francesco Maura, MD, discusses the significance of studying genomic defining events in patients with multiple myeloma.

Dr. Usmani on the Potential Future of Isatuximab in Multiple Myeloma

April 26th 2021

Saad Z. Usmani, MD, FACP, discusses the potential future utility of isatuximab-irfc in multiple myeloma.

EMA Validates Type II Variation Marketing Authorization Application for Selinexor Triplet in Multiple Myeloma

April 26th 2021

The European Medicines Agency has validated a Type II Variation Marketing Authorization Application to Karyopharm Therapeutics Inc. for selinexor in combination with bortezomib and low-dose dexamethasone as a treatment for adult patients with multiple myeloma who have received at least 1 prior therapy.

Dr. Shah on Future Directions With CAR T-Cell Therapy in Multiple Myeloma

April 23rd 2021

Nina Shah, MD, discusses potential future directions with CAR T-cell therapy in multiple myeloma.

Designer DNA Therapeutic Wipes Out Cancer Stem Cells, Treats Multiple Myeloma in Mice

April 23rd 2021

Study supports launch of Phase I clinical trial to test a designer DNA agent — an antisense oligonucleotide that targets a gene called IRF4 — in patients with multiple myeloma

Dr. Vij on the Integration of Selinexor in Relapsed/Refractory Multiple Myeloma

April 22nd 2021

Ravi Vij, MD, MBA, discusses the integration of selinexor into the relapsed/refractory multiple myeloma armamentarium.

Melphalan Flufenamide Emerges as Option for Heavily Pretreated Myeloma

April 22nd 2021

Joseph Mikhael, MD, MEd, FRCPC, FACP, discussed how melphalan flufenamide could potentially shift the treatment paradigm for patients with multiple myeloma.

Dr. Shah on the Clinical Significance of Ide-Cel in Myeloma

April 21st 2021

Nina Shah, MD, discusses the clinical significance of idecabtagene vicleucel for the treatment of patients with multiple myeloma.

FDA Grants RMAT Designation to ALLO-715 for Relapsed/Refractory Multiple Myeloma

April 21st 2021

The FDA granted a Regenerative Medicine Advanced Therapy designation to the allogeneic chimeric antigen receptor T-cell therapy as a potential treatment for patients with relapsed/refractory multiple myeloma.

Tocilizumab May Have Activity Against COVID-19–Associated Cytokine Storm in Myeloma

April 20th 2021

Tocilizumab may represent a potential treatment option with double action against cytokine storm due to COVID-19 in a subset of patients with active multiple myeloma and severe infection with the virus.

Dr. Usmani on Treatment Considerations for Second Relapse Myeloma and Beyond

April 20th 2021

Saad Z. Usmani, MD, FACP, discusses treatment considerations for patients with multiple myeloma who are in their second relapse or beyond.

Isatuximab Plus Carfilzomib/Dexamethasone Approved in Europe for Relapsed Myeloma

April 19th 2021

The European Commission has approved isatuximab for use in combination with carfilzomib and dexamethasone in the treatment of patients with relapsed multiple myeloma who have received at least 1 previous therapy.

Dr. Usmani on Optimizing Treatment Selection in Relapsed/Refractory Multiple Myeloma

April 16th 2021

Saad Z. Usmani, MD, FACP, discusses optimizing treatment selection in relapsed/refractory multiple myeloma.

Dr. Kröger on the Role of Allogenic Stem Cell Transplant in Multiple Myeloma

April 15th 2021

Nicolaus Kröger, MD, discusses the role of allogenic stem cell transplant in patients with multiple myeloma.

Dr. Costa on the Evolving Treatment Paradigm in Newly Diagnosed Multiple Myeloma

April 14th 2021

Luciano J. Costa, MD, PhD, discusses the evolving treatment paradigm in newly diagnosed multiple myeloma.

Dr. Vij on the Potential of CELMoDs in Relapsed/Refractory Multiple Myeloma

April 13th 2021

Ravi Vij, MD, MBA, discusses the potential of cereblon E3 ligase modulators in relapsed/refractory multiple myeloma.

Dr. Marron on an Adjuvant Personalized Neoantigen Peptide Vaccine for Several Malignancies

April 10th 2021

Thomas Urban Marron, MD, PhD, discusses primary objectives of a study examining the use of an adjuvant personalized neoantigen peptide vaccine in several malignancies.

Daratumumab Consolidation Appears Safe, Shows Encouraging Efficacy in Very Good Responders With Myeloma

April 9th 2021

Daratumumab appears to be safe when used as consolidation therapy in patients with multiple myeloma, even soon after autologous stem cell transplant, and the agent has also demonstrated early efficacy in the setting of very good responders.

Dr. Shah on Managing CAR T-Cell Therapy–Related Toxicities in Multiple Myeloma

April 7th 2021

Nina Shah, MD, discusses the management of CAR T-cell therapy–related toxicities in multiple myeloma.